This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head and neck.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study NRG HN003.
View study details on ClinicalTrials.gov
Subjects, 18 y/o and older, with a pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), hypopharynx or larynx.
June 01, 2018